Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial

Current pharmacologic treatments for pediatric anxiety disorders (e.g., selective serotonin reuptake inhibitors (SSRIs)) frequently use “one size fits all” dosing strategies based on average responses in clinical trials. However, for some SSRIs, including escitalopram, variation in CYP2C19 activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Strawn, Jeffrey R., Poweleit, Ethan A., Mills, Jeffrey A., Schroeder, Heidi K., Neptune, Zoe A., Specht, Ashley M., Farrow, Jenni E., Zhang, Xue, Martin, Lisa J., Ramsey, Laura B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621124/
https://www.ncbi.nlm.nih.gov/pubmed/34834540
http://dx.doi.org/10.3390/jpm11111188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621124/
https://www.ncbi.nlm.nih.gov/pubmed/34834540
http://dx.doi.org/10.3390/jpm11111188

Ejemplares similares